Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

For Thurs. Cannabis Investors: Should Aphria Inc. (TSX:APHA) or Aurora Cannabis Inc. (TSX:ACB) Stock Be in Your Portfolio?

Published 2018-12-06, 09:59 a/m
Updated 2018-12-06, 10:15 a/m
For Thurs. Cannabis Investors: Should Aphria Inc. (TSX:APHA) or Aurora Cannabis Inc. (TSX:ACB) Stock Be in Your Portfolio?

For Thurs. Cannabis Investors: Should Aphria Inc. (TSX:APHA) or Aurora Cannabis Inc. (TSX:ACB) Stock Be in Your Portfolio?

The extended pullback in marijuana stock prices from the September and October highs is now pushing some pot stocks to new 12-month lows.

Investors who bought cannabis stocks in the weeks and days leading up to the launch of the Canadian retail market might be feeling a bit uncomfortable right now. However, those who missed out on the big rally earlier this year are wondering if this is a good opportunity to start a new position in the marijuana sector.

Let’s take a look at Aphria (TSX:APHA)(NYSE:APHA) and Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if one might be an interesting pick today.

Aphria

Aphria took a huge hit in recent trading sessions after a short-seller report came out that suggests the company overpaid for assets in Latin America and the Caribbean. At the time of writing Aphria trades for $5 per share, compared to $11 a week ago and $20 in September.

Quintessential Capital Management (QCM) claims that Aphria’s recent purchases of assets in Jamaica, Argentina, and Colombia could prove to be worth significantly less than the acquisition price.

Opinions often vary on the value of assets in transactions and SOL Global Investments Corp., which sold the assets to Aphria, claims the allegations are false. Aphria is planning to respond to the claims, and investors will have to decide who to believe and whether there is a long-term effect on the company.

One concern might be the impact on a possible deal with a major beverage or tobacco partner. Canopy Growth and HEXO already have arrangements with beer companies, and Cronos recently acknowledged that it has been in talks with Altria (NYSE:MO).

Until the QMC issue is sorted out, potential partners could decide to stay on the sidelines or seek deals with other marijuana companies.

At the current stock price, Aphria has a market capitalization of $1.25 billion. If one of the other major players sees value in the company’s production facilities and supply contracts, a takeover offer could emerge while the stock is under pressure.

Aurora Cannabis

Aurora Cannabis trades at $6.20 per share, down from close to $8 last week and a closing high of $15 in October, just before the launch of the Canadian retail market.

The current price puts the market capitalization at $5 billion, which is still significant in the industry, but less than half the value of Canopy Growth and Tilray, the market leaders.

Rumours emerged a couple of months ago that Aurora Cannabis had talks with Coca-Cola (NYSE:KO), but no deal emerged and the drinks giant later said it was not pursuing a cannabis partnership.

Aurora Cannabis has been very aggressive in its acquisition strategy, buying both CanniMed and MedReleaf in deals of $1.1 billion and $2.5 billion. The company recently spent $290 million to buy ICC Labs to secure a position in South America.

Given the company’s appetite for scaling up quickly, it wouldn’t be a surprise to see Aurora Cannabis take a run at Aphria.

Is one attractive right now?

Despite the steep declines, all of the cannabis stocks remain expensive based on their current revenue. As such, investors should be careful when putting new money into the sector.

That said, there could be an opportunity for some big gains if sentiment shifts. Ongoing volatility should be expected, but investors who are positive on the long-term growth potential for the industry might want to start nibbling on additional downside.

Regarding these two companies, I would probably avoid Aphria until the dust settles on the QMC claims. Aurora Cannabis might be a better contrarian bet.

Fool contributor Andrew Walker has no position in any stock mentioned.

This Article Was First Published on The Motley Fool

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.